2017 Gene Sequencing in Public Health Newborn Screening Meeting

The 2017 Gene Sequencing in Public Health Newborn Screening Meeting, co-sponsored by APHL, CDC and HRSA,  addressed the current status of gene sequencing in newborn screening, and identified barriers and potential solutions for the successful incorporation of gene sequencing into newborn screening. Meeting attendees included newborn screening laboratory directors and follow up managers.

Meeting Agenda

Meeting Workbook

Thursday, February 16

 Welcome and Introductions
-Jelili Ojodu, MPH, Association of Public Health Laboratories
-Carla Cuthbert, PhD, FCCMG, FACMG, Centers for Disease Control and Prevention (CDC)

Introduction and Background of Gene Sequencing in NBS
-Suzanne Cordovado, PhD, CDC
  
Current Second Tier and Future Applications of Gene Sequencing in NBS
-Michele Caggana, ScD, FACMG, New York State Department of Health
-Colleen Stevens, PhD, New York State Department of Health

Mutation vs. Sequencing Data Pros and Cons
-Anne Comeau, PhD, University of Massachusetts Medical School

Instrumentation and Informatics Requirements
-Chris Greene, PhD, CDC
-Scott Sammons, MPH, CDC

Program Planning
-Yvonne Kellar-Guenther, PhD, Colorado School of Public Health, NewSTEPs


Friday, February 17

Recap of Day 1
-Rachel Lee, PhD, Texas Department of State Health Services

Sequencing Results Interpretation and Reporting
-Rachel Lee, PhD, Texas Department of State Health Services

Short-Term and Long-term Follow Up Needs
-Amy Gaviglio, MS, CGC, Minnesota Department of Health

Process to Brainstorm Solutions
-Yvonne Kellar-Guenther, PhD, Colorado School of Public Health, NewSTEPs

Introduction for Programs New to Sequencing
-Michele Caggana, ScD, FACMG, New York State Department of Health

Programs New to Sequencing
Scott Shone, PhD, New Jersey Division of Public Health & Environmental Laboratories

Choosing the Starting Point
-Yvonne Kellar-Guenther, PhD, Colorado School of Public Health, NewSTEPs